- Home
- PZC vs ENTA Comparison
PZC vs ENTA Comparison
Compare PZC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZC
- ENTA
- Stock Information
- Founded
- PZC 2002
- ENTA 1995
- Country
- PZC United States
- ENTA United States
- Employees
- PZC N/A
- ENTA N/A
- Industry
- PZC Investment Managers
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- PZC Finance
- ENTA Health Care
- Exchange
- PZC Nasdaq
- ENTA Nasdaq
- Market Cap
- PZC 150.3M
- ENTA 152.3M
- IPO Year
- PZC N/A
- ENTA 2013
- Fundamental
- Price
- PZC $6.86
- ENTA $8.13
- Analyst Decision
- PZC
- ENTA Buy
- Analyst Count
- PZC 0
- ENTA 4
- Target Price
- PZC N/A
- ENTA $17.25
- AVG Volume (30 Days)
- PZC 48.2K
- ENTA 485.1K
- Earning Date
- PZC 01-01-0001
- ENTA 02-10-2025
- Dividend Yield
- PZC 4.68%
- ENTA N/A
- EPS Growth
- PZC N/A
- ENTA N/A
- EPS
- PZC N/A
- ENTA N/A
- Revenue
- PZC N/A
- ENTA $66,590,999.00
- Revenue This Year
- PZC N/A
- ENTA N/A
- Revenue Next Year
- PZC N/A
- ENTA N/A
- P/E Ratio
- PZC N/A
- ENTA N/A
- Revenue Growth
- PZC N/A
- ENTA N/A
- 52 Week Low
- PZC $6.30
- ENTA $4.71
- 52 Week High
- PZC $8.20
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- PZC 56.75
- ENTA 77.82
- Support Level
- PZC $6.77
- ENTA $6.92
- Resistance Level
- PZC $6.79
- ENTA $8.76
- Average True Range (ATR)
- PZC 0.06
- ENTA 0.60
- MACD
- PZC 0.01
- ENTA 0.42
- Stochastic Oscillator
- PZC 80.00
- ENTA 93.05
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.